Replies to post #169732 on Biotech Values

[acgood]

MK-8931 (MRK, LGND)

This is a phase 2/3 study so has been enrolling in the phase 2 safety cohort for awhile. Data from this portion should be available shortly. There has not yet been anything to indicate they have formally advanced into phase 3